search
Back to results

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)

Primary Purpose

Colorectal Cancer

Status
Recruiting
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
XL092
Atezolizumab
Regorafenib
Sponsored by
Exelixis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Colorectal Cancer focused on measuring Colorectal Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects with histologically or cytologically confirmed adenocarcinoma of the colon or rectum.

    • Documented RAS status (mutant or wild-type [WT]), by tissue-based analysis.
    • Documented NOT to have microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) CRC by tissue-based analysis.

  • Has received standard-of-care (SOC) anticancer therapies as prior therapy for metastatic CRC and has radiographically progressed, is refractory or intolerant to these therapies.

    • Radiographic progression during treatment with or within 3 months following the last dose of the most recent approved SOC chemotherapy regimen.
  • Measurable disease according to RECIST v1.1 as determined by the Investigator.
  • Available archival tumor biopsy material. If archival tissue is unavailable, must provide fresh tumor tissue biopsy prior to randomization.
  • Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs) related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.
  • Age 18 years or older on the day of consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Adequate organ and marrow function.

Exclusion Criteria:

  • Prior treatment with XL092, regorafenib, trifluridine/tipiracil, or PD-L1/PD-1 targeting immune checkpoint inhibitors (ICIs).
  • Receipt of a small molecule kinase inhibitor (including investigational agents) within 2 weeks before randomization.
  • Receipt of any type of anticancer antibody therapy, systemic chemotherapy, or hormonal anti-cancer therapy within 3 weeks (or bevacizumab within 4 weeks) before randomization.
  • Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before randomization.
  • Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before randomization.
  • Concomitant anticoagulation with oral anticoagulants and platelet inhibitors.
  • Corrected QT interval calculated by the Fridericia formula (QTcF) > 460 ms within 10 days before randomization.
  • Pregnant or lactating females.
  • Administration of a live, attenuated vaccine within 30 days before randomization.

Sites / Locations

  • Exelixis Clinical Site #65Recruiting
  • Exelixis Clinical Site #30Recruiting
  • Exelixis Clinical Site #70Recruiting
  • Exelixis Clinical Site #9Recruiting
  • Exelixis Clinical Site #55Recruiting
  • Exelixis Clinical Site #77Recruiting
  • Exelixis Clinical Site #105Recruiting
  • Exelixis Clinical Site #80Recruiting
  • Exelixis Clinical Site #5Recruiting
  • Exelixis Clinical Site #82Recruiting
  • Exelixis Clinical Site #58Recruiting
  • Exelixis Clinical Site #81Recruiting
  • Exelixis Clinical Site #16Recruiting
  • Exelixis Clinical Site #60Recruiting
  • Exelixis Clinical Site #4Recruiting
  • Exelixis Clinical Site #3Recruiting
  • Exelixis Clinical Site #102Recruiting
  • Exelixis Clinical Site #10Recruiting
  • Exelixis Clinical Site #47Recruiting
  • Exelixis Clinical Site #7Recruiting
  • Exelixis Clinical Site #22Recruiting
  • Exelixis Clinical Site #8Recruiting
  • Exelixis Clinical Site #1Recruiting
  • Exelixis Clinical Site #15Recruiting
  • Exelixis Clinical Site #17Recruiting
  • Exelixis Clinical Site #11Recruiting
  • Exelixis Clinical Site #59Recruiting
  • Exelixis Clinical Site #74Recruiting
  • Exelixis Clinical Site #6Recruiting
  • Exelixis Clinical Site #12Recruiting
  • Exelixis Clinical Site #75Recruiting
  • Exelixis Clinical Site #106Recruiting
  • Exelixis Clinical Site #18Recruiting
  • Exelixis Clinical Site #103Recruiting
  • Exelixis Clinical Site #24Recruiting
  • Exelixis Clinical Site #56Recruiting
  • Exelixis Clinical Site #76Recruiting
  • Exelixis Clinical Site #450Recruiting
  • Exelixis Clinical Site #14Recruiting
  • Exelixis Clinical Site #13Recruiting
  • Exelixis Clinical Site #32Recruiting
  • Exelixis Clinical Site #89Recruiting
  • Exelixis Clinical Site #2Recruiting
  • Exelixis Clinical Site #83Recruiting
  • Exelixis Clinical Site #53Recruiting
  • Exelixis Clinical Site #97Recruiting
  • Exelixis Clinical Site #19Recruiting
  • Exelixis Clinical Site #23Recruiting
  • Exelixis Clinical Site #27Recruiting
  • Exelixis Clinical Site #64Recruiting
  • Exelixis Clinical Site #43Recruiting
  • Exelixis Clinical Site #51Recruiting
  • Exelixis Clinical Site #35Recruiting
  • Exelixis Clinical Site #52Recruiting
  • Exelixis Clinical Site #84Recruiting
  • Exelixis Clinical Site #88Recruiting
  • Exelixis Clinical Site #71Recruiting
  • Exelixis Clinical Site #87Recruiting
  • Exelixis Clinical Site #38Recruiting
  • Exelixis Clinical Site #93Recruiting
  • Exelixis Clinical Site #109Recruiting
  • Exelixis Clinical Site #113Recruiting
  • Exelixis Clinical Site #61Recruiting
  • Exelixis Clinical Site #63Recruiting
  • Exelixis Clinical Site #91Recruiting
  • Exelixis Clinical Site #25Recruiting
  • Exelixis Clinical Site #33Recruiting
  • Exelixis Clinical Site #41Recruiting
  • Exelixis Clinical Site #48Recruiting
  • Exelixis Clinical Site #36Recruiting
  • Exelixis Clinical Site #29Recruiting
  • Exelixis Clinical Site #28Recruiting
  • Exelixis Clinical Site #37Recruiting
  • Exelixis Clinical Site #34Recruiting
  • Exelixis Clinical Site #45Recruiting
  • Exelixis Clinical Site #66Recruiting
  • Exelixis Clinical Site #46Recruiting
  • Exelixis Clinical Site #54Recruiting
  • Exelixis Clinical Site #44Recruiting
  • Exelixis Clinical Site #40Recruiting
  • Exelixis Clinical Site #57Recruiting
  • Exelixis Clinical Site #49Recruiting
  • Exelixis Clinical Site #69Recruiting
  • Exelixis Clinical Site #104Recruiting
  • Exelixis Clinical Site #20Recruiting
  • Exelixis Clinical Site #68Recruiting
  • Exelixis Clinical Site #26Recruiting
  • Exelixis Clinical Site #42Recruiting
  • Exelixis Clinical Site #31Recruiting
  • Exelixis Clinical Site #108Recruiting
  • Exelixis Clinical Site #99Recruiting
  • Exelixis Clinical Site #96
  • Exelixis Clinical Site #100Recruiting
  • Exelixis Clinical Site #39Recruiting
  • Exelixis Clinical Site #98Recruiting
  • Exelixis Clinical Site #94Recruiting
  • Exelixis Clinical Site #78Recruiting
  • Exelixis Clinical Site #21Recruiting
  • Exelixis Clinical Site #86Recruiting
  • Exelixis Clinical Site #112Recruiting
  • Exelixis Clinical Site #95Recruiting
  • Exelixis Clinical Site #72Recruiting
  • Exelixis Clinical Site #67Recruiting
  • Exelixis Clinical Site #79Recruiting
  • Exelixis Clinical Site #90Recruiting
  • Exelixis Clinical Site #85Recruiting
  • Exelixis Clinical Site #107Recruiting
  • Exelixis Clinical Site #73Recruiting
  • Exelixis Clinical Site #101Recruiting
  • Exelixis Clinical Site #62Recruiting
  • Exelixis Clinical Site #92Recruiting
  • Exelixis Clinical Site #110Recruiting
  • Exelixis Clinical Site #111Recruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Experimental Arm

Control Arm

Arm Description

Subjects with mCRC will receive XL092 + atezolizumab

Subjects with mCRC will receive active comparator of regorafenib

Outcomes

Primary Outcome Measures

Efficacy in RAS wild-type (WT) subjects
The primary objective of this study is to evaluate the efficacy of XL092 + atezolizumab versus regorafenib in subjects with RAS wild-type MSS/MSI-low mCRC who have progressed after or are intolerant to SOC therapy.
Duration of Overall Survival (OS)
Defined as the time from randomization to death due to any cause

Secondary Outcome Measures

Full Information

First Posted
June 16, 2022
Last Updated
October 16, 2023
Sponsor
Exelixis
search

1. Study Identification

Unique Protocol Identification Number
NCT05425940
Brief Title
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Acronym
STELLAR-303
Official Title
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 7, 2022 (Actual)
Primary Completion Date
August 2025 (Anticipated)
Study Completion Date
February 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Exelixis

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multicenter, randomized, open-label, controlled Phase 3 trial of XL092 + atezolizumab vs regorafenib in subjects with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed after or are intolerant to standard-of-care (SOC) therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Cancer
Keywords
Colorectal Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
600 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Experimental Arm
Arm Type
Experimental
Arm Description
Subjects with mCRC will receive XL092 + atezolizumab
Arm Title
Control Arm
Arm Type
Active Comparator
Arm Description
Subjects with mCRC will receive active comparator of regorafenib
Intervention Type
Drug
Intervention Name(s)
XL092
Intervention Description
Supplied as tablets; administered orally daily
Intervention Type
Drug
Intervention Name(s)
Atezolizumab
Other Intervention Name(s)
Tecentriq®
Intervention Description
Supplied as 1200 mg/20 mL vials; administered as a 1200 mg IV infusion once in a 3-week cycle (q3w)
Intervention Type
Drug
Intervention Name(s)
Regorafenib
Other Intervention Name(s)
Stivarga®
Intervention Description
Supplied as 40 mg tablets; administered orally daily at 160 mg for the first 21 days of each 28-day cycle
Primary Outcome Measure Information:
Title
Efficacy in RAS wild-type (WT) subjects
Description
The primary objective of this study is to evaluate the efficacy of XL092 + atezolizumab versus regorafenib in subjects with RAS wild-type MSS/MSI-low mCRC who have progressed after or are intolerant to SOC therapy.
Time Frame
Approximately 26 months after the first subject is randomized
Title
Duration of Overall Survival (OS)
Description
Defined as the time from randomization to death due to any cause
Time Frame
Approximately 26 months after the first subject is randomized
Other Pre-specified Outcome Measures:
Title
Duration of Progression-Free Survival (PFS) as assessed by the Investigator per RECIST 1.1
Description
Defined as the time randomization to the earlier of either radiographic progressive disease (PD) as assessed by the Investigator per RECIST 1.1 or death from any cause
Time Frame
Approximately 26 months after the first subject is randomized
Title
Objective Response Rate (ORR) as assessed by the Investigator per RECIST 1.1
Description
Defined as the proportion of subjects experiencing a confirmed complete response (CR) or confirmed partial response (PR) per as assessed by the Investigator RECIST 1.1 criteria
Time Frame
Up to 36 months after the first subject is randomized
Title
Duration of Response (DOR) as assessed by the Investigator per RECIST 1.1
Description
Defined as the time from the first documentation of objective response (subsequently confirmed at a visit ≥ 28 days later) to disease progression or death due to any cause
Time Frame
Up to 36 months after the first subject is randomized
Title
Change in tumor markers from baseline
Time Frame
Up to 36 months after the first subject is randomized

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects with histologically or cytologically confirmed adenocarcinoma of the colon or rectum. Documented RAS status (mutant or wild-type [WT]), by tissue-based analysis. Documented NOT to have microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) CRC by tissue-based analysis. Has received standard-of-care (SOC) anticancer therapies as prior therapy for metastatic CRC and has radiographically progressed, is refractory or intolerant to these therapies. Radiographic progression during treatment with or within 3 months following the last dose of the most recent approved SOC chemotherapy regimen. Measurable disease according to RECIST v1.1 as determined by the Investigator. Available archival tumor biopsy material. If archival tissue is unavailable, must provide fresh tumor tissue biopsy prior to randomization. Recovery to baseline or ≤ Grade 1 severity (CTCAE v5) from adverse events (AEs) related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy. Age 18 years or older on the day of consent. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. Adequate organ and marrow function. Exclusion Criteria: Prior treatment with XL092, regorafenib, trifluridine/tipiracil, or PD-L1/PD-1 targeting immune checkpoint inhibitors (ICIs). Receipt of a small molecule kinase inhibitor (including investigational agents) within 2 weeks before randomization. Receipt of any type of anticancer antibody therapy, systemic chemotherapy, or hormonal anti-cancer therapy within 3 weeks (or bevacizumab within 4 weeks) before randomization. Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 4 weeks before randomization. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks before randomization. Concomitant anticoagulation with oral anticoagulants and platelet inhibitors. Corrected QT interval calculated by the Fridericia formula (QTcF) > 460 ms within 10 days before randomization. Pregnant or lactating females. Administration of a live, attenuated vaccine within 30 days before randomization.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Exelixis Clinical Trials
Phone
1-888-EXELIXIS (888-393-5494)
Email
druginfo@exelixis.com
First Name & Middle Initial & Last Name or Official Title & Degree
Backup or International
Phone
650-837-7400
Facility Information:
Facility Name
Exelixis Clinical Site #65
City
Jonesboro
State/Province
Alabama
ZIP/Postal Code
72401
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #30
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85004
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #70
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85719
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #9
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #55
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #77
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #105
City
Orange
State/Province
California
ZIP/Postal Code
92868-3201
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #80
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #5
City
Santa Rosa
State/Province
California
ZIP/Postal Code
95403
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #82
City
Sylmar
State/Province
California
ZIP/Postal Code
91342-1438
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #58
City
Torrance
State/Province
California
ZIP/Postal Code
90505
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #81
City
Whittier
State/Province
California
ZIP/Postal Code
90602-1002
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #16
City
Miami Beach
State/Province
Florida
ZIP/Postal Code
33140
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #60
City
Orlando
State/Province
Florida
ZIP/Postal Code
32804
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #4
City
Marietta
State/Province
Georgia
ZIP/Postal Code
30060
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #3
City
Joliet
State/Province
Illinois
ZIP/Postal Code
60435
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #102
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46250
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #10
City
Westwood
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #47
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40536
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #7
City
New Orleans
State/Province
Louisiana
ZIP/Postal Code
70112
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #22
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #8
City
Billings
State/Province
Montana
ZIP/Postal Code
59102
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #1
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68130
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #15
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87131
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #17
City
Bronx
State/Province
New York
ZIP/Postal Code
10461
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #11
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #59
City
New York
State/Province
New York
ZIP/Postal Code
10029
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #74
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28204
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #6
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #12
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73142
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #75
City
Portland
State/Province
Oregon
ZIP/Postal Code
97210
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #106
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #18
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15212
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #103
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15232
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #24
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29607
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #56
City
Chattanooga
State/Province
Tennessee
ZIP/Postal Code
37404
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #76
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #450
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #14
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24014
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #13
City
Seattle
State/Province
Washington
ZIP/Postal Code
98101
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #32
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #89
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #2
City
Spokane
State/Province
Washington
ZIP/Postal Code
99208
Country
United States
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #83
City
Albury
ZIP/Postal Code
2640
Country
Australia
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #53
City
Bankstown
ZIP/Postal Code
2200
Country
Australia
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #97
City
Heidelberg
ZIP/Postal Code
3084
Country
Australia
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #19
City
Melbourne
ZIP/Postal Code
3002
Country
Australia
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #23
City
Melbourne
ZIP/Postal Code
3021
Country
Australia
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #27
City
Port Macquarie
ZIP/Postal Code
2444
Country
Australia
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #64
City
Woodville South
ZIP/Postal Code
5011
Country
Australia
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #43
City
Antwerp
ZIP/Postal Code
2300
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #51
City
Brussels
ZIP/Postal Code
1200
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #35
City
Namur
ZIP/Postal Code
5000
Country
Belgium
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #52
City
Besançon
ZIP/Postal Code
25030
Country
France
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #84
City
Dijon
ZIP/Postal Code
21079
Country
France
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #88
City
Herbault
ZIP/Postal Code
34298
Country
France
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #71
City
Lyon
ZIP/Postal Code
69008
Country
France
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #87
City
Marseille
ZIP/Postal Code
13385
Country
France
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #38
City
Paris
ZIP/Postal Code
75020
Country
France
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #93
City
Suresnes
ZIP/Postal Code
92150
Country
France
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #109
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #113
City
Frankfurt am Main
ZIP/Postal Code
60488
Country
Germany
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #61
City
Hamburg
ZIP/Postal Code
20249
Country
Germany
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #63
City
Hamburg
ZIP/Postal Code
22763
Country
Germany
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #91
City
München
ZIP/Postal Code
81737
Country
Germany
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #25
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #33
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #41
City
Budapest
ZIP/Postal Code
1097
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #48
City
Debrecen
ZIP/Postal Code
4302
Country
Hungary
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #36
City
Goyang-si
ZIP/Postal Code
10408
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #29
City
Gyeonggi-do
ZIP/Postal Code
14068
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #28
City
Hwasun
ZIP/Postal Code
58128
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #37
City
Seongnam-si
ZIP/Postal Code
13620
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #34
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #45
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #66
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #46
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #54
City
Seoul
ZIP/Postal Code
06591
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #44
City
Seoul
ZIP/Postal Code
08308
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #40
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #57
City
Auckland
ZIP/Postal Code
1023
Country
New Zealand
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #49
City
Dunedin
ZIP/Postal Code
9016
Country
New Zealand
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #69
City
Hamilton
ZIP/Postal Code
3204
Country
New Zealand
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #104
City
Wellington
ZIP/Postal Code
6021
Country
New Zealand
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #20
City
Bydgoszcz
ZIP/Postal Code
85-796
Country
Poland
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #68
City
Opole
ZIP/Postal Code
45-061
Country
Poland
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #26
City
Siedlce
ZIP/Postal Code
08-110
Country
Poland
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #42
City
Tomaszów Mazowiecki
ZIP/Postal Code
97-200
Country
Poland
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #31
City
Warszawa
ZIP/Postal Code
02-507
Country
Poland
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #108
City
Almada
ZIP/Postal Code
2805-267
Country
Portugal
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #99
City
Guimarães
ZIP/Postal Code
4835-044
Country
Portugal
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #96
City
Lisboa
ZIP/Postal Code
400-038
Country
Portugal
Individual Site Status
Not yet recruiting
Facility Name
Exelixis Clinical Site #100
City
Singapore
ZIP/Postal Code
168583
Country
Singapore
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #39
City
Singapore
ZIP/Postal Code
217562
Country
Singapore
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #98
City
Singapore
ZIP/Postal Code
258499
Country
Singapore
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #94
City
Singapore
ZIP/Postal Code
329563
Country
Singapore
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #78
City
Barcelona
ZIP/Postal Code
08023
Country
Spain
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #21
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #86
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #112
City
Barcelona
ZIP/Postal Code
08908
Country
Spain
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #95
City
Lleida
ZIP/Postal Code
25198
Country
Spain
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #72
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #67
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #79
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #90
City
Valencia
ZIP/Postal Code
46014
Country
Spain
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #85
City
Kaohsiung
ZIP/Postal Code
807
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #107
City
Kaohsiung
ZIP/Postal Code
833
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #73
City
Taichung
ZIP/Postal Code
40447
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #101
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #62
City
Chiang Mai
ZIP/Postal Code
50200
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #92
City
Hat Yai
ZIP/Postal Code
90110
Country
Thailand
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #110
City
Birmingham
ZIP/Postal Code
B95SS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Name
Exelixis Clinical Site #111
City
Edinburgh
ZIP/Postal Code
EH42XU
Country
United Kingdom
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer

We'll reach out to this number within 24 hrs